New Crown Vaccine Express! AstraZeneven/Oxford UNIVERSITY AZD1222 is approved by the Eu union: routine refrigeration, 2-pin immunity, global non-profit supply!

January 30, 2021 // -- At present, the outbreak of new crown pneumonia abroad is still spreading rapidly.
according to Baidu's Real-Time Big Data Report on the Outbreak of New Coronavirus Pneumonia, as of 12 p.m. on January 30, 2021, more than 100 million cases (102.63 million) had been confirmed worldwide and more than 2.216 million deaths had occurred.
recently, AstraZeneca/Oxford University's adenovirus vaccine COVID-19 Vaccine AstraZeneca (formerly known as AZD1222) had good regulatory news.
The European Commission (EC) has granted COVID-19 Vaccine AstraZeneca Conditional Listing Permit (CMA) for active immunization of people 18 years of age and older to prevent new coronavirus pneumonia (COVID-19) caused by the new coronavirus (SARS-CoV-2).
with this approval, AstraZeneta is now working with the EU to proactively immunized all EU member states.
after reviewing the application, the European Medicines Agency (EMA) Human Medicines Products Committee (CHMP) gave positive advice after a rolling review of the Oxford-led Phase 3 project analysis.
the vaccine will continue to accumulate from ongoing clinical trials and is expected to be released in the coming weeks.
CHMP recommends injecting 2 doses of COVID-19 Vaccine AstraZeneca vaccine at intervals of 4-12 weeks in people 18 years and older.
clinical trials have shown that the immunization programme is safe and effective in preventing symptomatic COVID-19, with no serious cases or hospitalizations 14 days after the second injection of immunization.
it is worth mentioning that the COVID-19 Vaccine AstraZeneca vaccine can be stored, transported and treated for at least 6 months under conventional refrigeration conditions (2-8 degrees C/36-46 degrees Fahrenheit) and used in existing medical settings.
two mRNA vaccines from Pfizer/BioNTech and Moderna, while highly efficient, require storage and distribution at minus 70 degrees Celsius, with significant limitations. Pascal Soriot, chief executive of
AstraZeneta, said: "Today's approval highlights the value of AstraZeneta's COVID-19 vaccine, which is not only effective and well-to-treat, but also easy to manage and, importantly, completely protects against serious illness and hospitalization.
we are very grateful to Oxford University, clinical trial participants and AstraZeneta colleagues for their unwavering commitment to providing this life-saving vaccine to millions of Europeans.
Professor Andrew Pollard, director of the Oxford Vaccine Group and lead researcher on the Oxford Vaccine Trials, said: "The European Commission's approval is an important milestone in expanding the use of the Oxford/AstraZenecom vaccine in our region and provides further recognition that the vaccine can be used to help protect populations from the COVID-19 pandemic after a rigorous review by regulators.
" AstraZeneta continues to work with regulators around the world to support their ongoing rolling review of emergency supply or conditional approvals during a health crisis.
is also seeking the World Health Organization's Emergency Use Listing to speed up access to vaccine supplies in low-income countries.
AstraZeneta continues to work with governments, international organizations and partners around the world to ensure widespread and equitable access to vaccines during the COVID-19 pandemic without any profit.
COVID-19 Vaccine AstraZeneca (formerly known as AZD1222) was co-invented by Oxford University and its spin-off company, Vaccitech.
it uses a weakened version based on the common cold virus (adenovirus) to replicate the defective chimpanzee virus vector, which causes infection in chimpanzees and contains genetic material for the SARS-CoV-2 virus prickly protein.
the vaccine, it produces surface prickly proteins that stimulate the immune system to attack the SARS-CoV-2 virus.
CHMP's recommendations are based on an analysis of 23,745 participants aged 18 and over who accumulated 232 symptomatic COVID-19 infections in phase III trials in the UK and Brazil conducted at Oxford University.
safety data released so far from more than 20,000 participants in four clinical trials in the UK, Brazil and South Africa.
article in The Lancet confirms that AstraZeneta's COVID-19 vaccine is well-to-do and that no serious vaccine-related safety incidents have been confirmed.
participants come from different ethnic and geographic groups and are physically healthy or have stable underlying diseases.
as well as the Oxford-led scheme, AstraZeneta is conducting large-scale trials in the US and around the world.
oxford and AstraZeneta are expected to recruit up to 60,000 subjects worldwide.
So far, AstraZenecom/Oxford University's COVID-19 vaccine has been granted CMA or Emergency Use Authorization (EUA) in nearly 40 countries, covering four continents, including the European Union, some Latin American countries, India, Morocco and the United Kingdom.
() original source: COVID-19 Vaccine AstraZeneca authorized for use in the EU